Laboratory Company Top Insiders

LH Stock  USD 216.57  3.05  1.43%   
Laboratory's insiders are aggressively selling. The analysis of insiders' sentiment of trading Laboratory stock suggests that almost all insiders are panicking at this time. Laboratory employs about 57 K people. The company is managed by 43 executives with a total tenure of roughly 304 years, averaging almost 7.0 years of service per executive, having 1324.42 employees per reported executive.
Deborah Tanner  CEO
CEO - Covance Drug Development (Covance)
John Ratliff  CEO
Chief Executive Officer - Covance Drug Development

Laboratory's Insider Buying Vs Selling

0

 
Selling
 
Buying

Latest Trades

2024-03-07Mark S SchroederDisposed 5048 @ 218.45View
2024-02-21Jonathan P DivincenzoDisposed 500 @ 215.49View
2024-02-13Der Vaart Sandra D VanDisposed 237 @ 226.45View
2024-02-08Der Vaart Sandra D VanDisposed 259 @ 222.06View
2023-11-16Peter J WilkinsonDisposed 1384 @ 210.71View
2023-08-22Dan SullivanDisposed @ 214.78
2023-08-08Kerrii B AndersonDisposed 5000 @ 211.57View
2023-06-29Der Vaart Sandra D VanDisposed 212 @ 240View
2023-05-19Paul R KirchgraberDisposed 4300 @ 216.91View
2023-05-18Mark S SchroederDisposed 1500 @ 216.77View
2023-03-31Mark S SchroederDisposed 3897 @ 225.81View
Monitoring Laboratory's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Laboratory. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate.
For more detail on how to invest in Laboratory Stock please use our How to Invest in Laboratory guide.

Laboratory's Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Laboratory's future performance. Based on our forecasts, it is anticipated that Laboratory will maintain a workforce of under 56950 employees by April 2024.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

Laboratory's latest congressional trading

Congressional trading in companies like Laboratory, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Laboratory by those in governmental positions are based on the same information available to the general public.
2023-08-22Senator Daniel S SullivanAcquired Under $15KVerify
2020-12-16Representative Susie LeeDisposed Under $15KVerify
2020-03-18Representative Gilbert CisnerosDisposed Under $15KVerify
2020-01-09Representative Mike GallagherDisposed Under $15KVerify
2019-04-26Senator James M InhofeAcquired $50K to $100KVerify
2019-04-26Senator James M. InhofeAcquired $50K to $100KVerify
2018-09-05Representative Bradley S. SchneiderDisposed $250K to $500KVerify

Laboratory Management Team Effectiveness

The company has Return on Asset (ROA) of 0.0377 % which means that for every $100 of assets, it generated a profit of $0.0377. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.0423 %, which means that it produced $0.0423 on every 100 dollars invested by current stockholders. Laboratory's management efficiency ratios could be used to measure how well Laboratory manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Capital Employed is estimated to decrease to 0.08. The current Return On Assets is estimated to decrease to 0.02. As of now, Laboratory's Total Current Assets are increasing as compared to previous years. The Laboratory's current Other Assets is estimated to increase to about 531.7 M, while Non Currrent Assets Other are projected to decrease to under 270.8 M.
The Laboratory's current Common Stock Shares Outstanding is estimated to increase to about 96.2 M. The Laboratory's current Net Income Applicable To Common Shares is estimated to increase to about 1.5 B

Laboratory Workforce Comparison

Laboratory is currently regarded as number one stock in number of employees category among related companies. The total workforce of Health Care industry is now estimated at about 78,028. Laboratory totals roughly 56,950 in number of employees claiming about 73% of equities under Health Care industry.

Laboratory Profit Margins

The company has Net Profit Margin (PM) of 0.03 %, which suggests that even a small decline in it sales will erase profits and may result in a net loss, or a negative profit margin. This is way below average. Likewise, it shows Net Operating Margin (NOM) of 0.07 %, which signifies that for every $100 of sales, it has a net operating income of $0.07.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.420.2586
Way Up
Slightly volatile
Net Profit Margin0.06740.0344
Way Up
Slightly volatile
Operating Profit Margin0.180.0924
Way Up
Slightly volatile
Pretax Profit Margin0.04440.0468
Notably Down
Slightly volatile
Return On Assets0.02370.025
Notably Down
Slightly volatile
Return On Equity0.05040.0531
Notably Down
Slightly volatile

Laboratory Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Laboratory insiders, such as employees or executives, is commonly permitted as long as it does not rely on Laboratory's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Laboratory insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-03-01
0.8953
77
86
 159,788 
 85,074 
2023-12-01
0.5
2
4
 436.00 
 1,839 
2023-09-01
0.3333
1
3
 56.00 
 5,073 
2023-06-01
2.0
22
11
 158,353 
 15,832 
2023-03-01
0.9111
82
90
 225,878 
 89,157 
2022-12-01
0.7273
8
11
 38,739 
 30,103 
2022-09-01
0.2941
5
17
 32,917 
 104,216 
2022-03-01
0.9186
79
86
 156,968 
 58,112 
2021-12-01
0.2941
5
17
 17,058 
 26,724 
2021-09-01
0.5
2
4
 4,550 
 9,065 
2021-06-01
0.4286
3
7
 8,110 
 18,162 
2021-03-01
0.9
72
80
 135,493 
 47,163 
2020-12-01
0.4286
6
14
 17,229 
 27,598 
2020-09-01
0.5
3
6
 2,420 
 5,443 
2020-06-01
0.2
1
5
 1,010 
 33,504 
2020-03-01
0.9605
73
76
 293,460 
 118,837 
2019-12-01
1.0
9
9
 147,524 
 36,645 
2019-09-01
0.2222
2
9
 5,066 
 26,216 
2019-06-01
0.5263
10
19
 148,322 
 92,882 
2019-03-01
0.8906
57
64
 197,097 
 73,462 
2018-12-01
0.5
2
4
 6,874 
 8,360 
2018-09-01
0.25
1
4
 153.00 
 2,306 
2018-06-01
0.25
5
20
 128,553 
 253,615 
2018-03-01
0.8947
68
76
 341,205 
 239,230 
2017-09-01
0.381
8
21
 213,123 
 439,693 
2017-06-01
0.8
4
5
 17,432 
 11,573 
2017-03-01
0.8312
64
77
 350,653 
 176,413 
2016-12-01
1.0
2
2
 49,901 
 31,601 
2016-09-01
0.2
1
5
 992.00 
 11,161 
2016-06-01
0.3
3
10
 200,450 
 411,918 
2016-03-01
0.7179
56
78
 312,339 
 252,898 
2015-12-01
0.25
2
8
 3,146 
 6,006 
2015-09-01
0.375
3
8
 119,990 
 229,576 
2015-06-01
0.2632
5
19
 57,060 
 113,853 
2015-03-01
0.6667
44
66
 144,102 
 159,333 
2014-12-01
0.3333
1
3
 624.00 
 1,718 
2014-09-01
0.3
3
10
 195,700 
 393,400 
2014-06-01
1.1053
21
19
 127,379 
 191,432 
2014-03-01
0.4138
12
29
 125,329 
 145,306 
2013-12-01
0.6
6
10
 100,024 
 188,800 
2013-09-01
0.5
4
8
 100,000 
 132,429 
2013-06-01
0.6296
17
27
 320,270 
 584,451 
2013-03-01
0.4706
8
17
 105,453 
 41,638 
2012-09-01
0.625
5
8
 149,294 
 254,830 
2012-06-01
3.0
9
3
 285,700 
 5,687 
2012-03-01
0.5
15
30
 260,005 
 274,061 
2011-12-01
0.5
1
2
 20,000 
 40,000 
2011-09-01
0.6667
2
3
 1,353 
 2,170 
2011-06-01
1.3333
12
9
 22,792 
 22,909 
2011-03-01
0.6207
18
29
 438,936 
 102,157 
2010-12-01
0.375
3
8
 65,366 
 132,494 
2010-09-01
0.75
3
4
 14,096 
 4,716 
2010-06-01
1.4286
10
7
 31,000 
 36,686 
2010-03-01
0.65
13
20
 487,600 
 78,161 
2009-12-01
0.2
1
5
 4,116 
 22,080 
2009-09-01
1.0
2
2
 50,700 
 854.00 
2009-06-01
2.0
8
4
 19,200 
 33,707 
2009-03-01
0.5217
12
23
 608,000 
 25,320 
2008-06-01
0.371
23
62
 568,776 
 12,548 
2008-03-01
0.0755
33
437
 354,093 
 385,564 
2007-12-01
0.7143
15
21
 35,260 
 72,386 
2007-09-01
1.5455
17
11
 95,452 
 95,856 
2007-06-01
0.3218
28
87
 39,074 
 82,599 
2007-03-01
0.3179
48
151
 631,190 
 228,173 
2006-12-01
1.3636
15
11
 14,288 
 28,000 
2006-09-01
1.0556
19
18
 27,060 
 53,993 
2006-06-01
0.5962
31
52
 90,974 
 170,945 
2006-03-01
0.1429
57
399
 976,027 
 1,306,343 
2005-12-01
1.6667
15
9
 13,996 
 29,233 
2005-09-01
2.25
18
8
 61,125 
 121,546 
2005-06-01
0.7273
32
44
 101,455 
 174,097 
2005-03-01
0.1489
35
235
 505,023 
 713,208 
2004-12-01
0.5972
43
72
 546,198 
 1,089,771 
2004-09-01
9.0
18
2
 3,303 
 286.00 
2004-06-01
0.6735
33
49
 143,456 
 206,000 
2004-03-01
0.1051
29
276
 691,714 
 812,942 
2003-12-01
0.6154
16
26
 64,604 
 70,000 
2003-09-01
0.6
12
20
 19,700 
 62,962 

Laboratory Notable Stakeholders

A Laboratory stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Laboratory often face trade-offs trying to please all of them. Laboratory's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Laboratory's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Deborah TannerCEO - Covance Drug Development (Covance)Profile
John RatliffChief Executive Officer - Covance Drug DevelopmentProfile
Gary HuffCEO, LabCorp DiagnosticsProfile
Paul KirchgraberExecutive Vice President and Chief Executive Officer - Covance Drug DevelopmentProfile
James BoyleExecutive VP and CEO of Labcorp DiagnosticsProfile
David KingChairman of the Board, President, Chief Executive OfficerProfile
Adam SchechterChairman of the Board, President, Chief Executive OfficerProfile
William KlitgaardPresident- Enlighten HealthProfile
Glenn EisenbergChief Financial Officer, Executive Vice PresidentProfile
Stephen AndersonVice President Investor RelationsProfile
Lance BerberianExecutive Vice President, Chief Technology Officer, Chief Information OfficerProfile
JD MDPresident EVPProfile
Peter WilkinsonSenior Vice President, Chief Accounting OfficerProfile
Lisa UthgenanntChief Human Resource Officer, Senior Vice PresidentProfile
Brian CaveneyExecutive Vice President, President, Diagnostics and Chief Medical OfficerProfile
Mark BrecherSenior Vice President Chief Medical OfficerProfile
Samuel EbertsSenior Vice President Chief Compliance Officer, Secretary, Chief Legal OfficerProfile
Sandra VaartExecutive Vice President, Chief Legal Officer, Chief Compliance Officer and SecretaryProfile
Scott FrommerVice President - Investor RelationsProfile
Edward DodsonChief Accounting Officer and Sr. VPProfile
Sanders WilliamsIndependent DirectorProfile
Kerrii AndersonIndependent DirectorProfile
JeanLuc BelingardIndependent DirectorProfile
Peter NeupertLead Independent DirectorProfile
Richelle ParhamIndependent DirectorProfile
Robert WilliamsIndependent DirectorProfile
Jeffrey DavisIndependent DirectorProfile
Garheng KongIndependent DirectorProfile
Gary GillilandIndependent DirectorProfile
Robert MittelstaedtLead Independent DirectorProfile
Paul SurdezIR Contact OfficerProfile
Judith SeltzChief Human Resource Officer, Executive Vice PresidentProfile
Michelle AbelsonLaboratory OperationsProfile
Amy SummyExecutive Vice President Chief Marketing OfficerProfile
Mark SchroederExecutive Vice President and Presidentident of Diagnostics Laboratory Operations and Global Supply ChainProfile
Paul MDEx DevelProfile
Marcia EisenbergChief VPProfile
D GillilandIndependent DirectorProfile
Clarissa WillettIR Contact OfficerProfile
Kathryn WengelIndependent DirectorProfile
Christin ODonnellVice RelationsProfile
Chas CookVP RelationsProfile
MPH MDPres VPProfile

About Laboratory Management Performance

The success or failure of an entity such as Laboratory often depends on how effective the management is. Laboratory management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Laboratory management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Laboratory management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for 2024
Return On Capital Employed 0.08  0.08 
Return On Assets 0.02  0.02 
Return On Equity 0.05  0.05 
The data published in Laboratory's official financial statements usually reflect Laboratory's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Laboratory. For example, before you start analyzing numbers published by Laboratory accountants, it's critical to develop an understanding of what Laboratory's liquidity, profitability, and earnings quality are in the context of the Health Care Providers & Services space in which it operates.
Please note, the presentation of Laboratory's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Laboratory's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Laboratory's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Laboratory. Please utilize our Beneish M Score to check the likelihood of Laboratory's management manipulating its earnings.

Laboratory Workforce Analysis

Traditionally, organizations such as Laboratory use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Laboratory within its industry.

Laboratory Manpower Efficiency

Return on Laboratory Manpower

Revenue Per Employee213.5K
Revenue Per Executive282.8M
Net Income Per Employee6.7K
Net Income Per Executive8.8M
Working Capital Per Employee9.5K
Working Capital Per Executive12.6M
When determining whether Laboratory offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Laboratory's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Laboratory Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Laboratory Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Laboratory. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate.
For more detail on how to invest in Laboratory Stock please use our How to Invest in Laboratory guide.
Note that the Laboratory information on this page should be used as a complementary analysis to other Laboratory's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.

Complementary Tools for Laboratory Stock analysis

When running Laboratory's price analysis, check to measure Laboratory's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Laboratory is operating at the current time. Most of Laboratory's value examination focuses on studying past and present price action to predict the probability of Laboratory's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Laboratory's price. Additionally, you may evaluate how the addition of Laboratory to your portfolios can decrease your overall portfolio volatility.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
CEOs Directory
Screen CEOs from public companies around the world
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Equity Valuation
Check real value of public entities based on technical and fundamental data
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Fundamental Analysis
View fundamental data based on most recent published financial statements
Is Laboratory's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Laboratory. If investors know Laboratory will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Laboratory listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.46)
Dividend Share
2.88
Earnings Share
4.33
Revenue Per Share
139.628
Quarterly Revenue Growth
0.035
The market value of Laboratory is measured differently than its book value, which is the value of Laboratory that is recorded on the company's balance sheet. Investors also form their own opinion of Laboratory's value that differs from its market value or its book value, called intrinsic value, which is Laboratory's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Laboratory's market value can be influenced by many factors that don't directly affect Laboratory's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Laboratory's value and its price as these two are different measures arrived at by different means. Investors typically determine if Laboratory is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Laboratory's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.